Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Merck opens first climate-neutral manufacturing facility in Ireland
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
